SEARCH

SEARCH BY CITATION

References

  • 1
    Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341:14471457.
  • 2
    Materson BJ. Calcium channel blockers: is it time to split the lump? Am J Hypertens. 1995;8:325329.
  • 3
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension. 2003;42:12061252.
  • 4
    Littlejohns P, Ranson P, Sealey C, et al; For the National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care (partial update of NICE Clinical Guideline 18). National Institute for Health and Clinical Excellence. http://www.nice.org.uk/page.aspx?o=278167 . Accessed June 25, 2006.
  • 5
    Cleophas TJ, van Marun R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol. 2001;87:487490.
  • 6
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
  • 7
    Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2010;170: 427. epub Nov 8, 2010; doi: 10.1001/archinternmmed.2010.
  • 8
    Agodoa LY, Appel L, Bakris GL, et al; For the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:27192728.
  • 9
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. Collaborative Study Group. N Engl J Med. 2001;345:841860.
  • 10
    Black HR, Elliott WJ, Grandits G, et al; For the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA. 2003;289:20732082.
  • 11
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. The INVEST Investigators. JAMA. 2003;290:28052816.
  • 12
    Hansson L, Hedner T, Lund-Johansen P, et al; For the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. Lancet. 2000;356:359365.
  • 13
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366372.
  • 14
    Hansson L, Zanchetti A, Julius S, et al; On behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:17551762.
  • 15
    Liu L, Zhang Y, Liu G, et al; For the FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:21572172.
  • 16
    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895906.
  • 17
    Jamerson K, Weber MA, Bakris GL, et al.; For the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:24172428.